« April 2007

Acomplia is Approved in Brazil for the Treatment of Obese Patients
April 27, 2007

Acomplia (rimonabant) is Approved in Brazil for the Treatment of Obese Patients, or Overweight Patients with Associated Risk Factors, Such as Type 2 Diabetes or Dyslipidemia

PARIS - April 26, 2007 - Sanofi-aventis announced today that the ANVISA, the Brazilian Health Authority, has granted marketing authorisation for Acomplia (rimonabant), in the following indication:

Acomplia is indicated as an adjunct to diet and exercise for the treatment of obese patients (Body Mass Index - BMI above or equal to 30 kg/m2), or overweight patients (BMI above 27 kg/m2) with associated risk factors, such as type 2 diabetes or dyslipidemia.

Acomplia is the first member of a new therapeutic class: the CB1 receptor antagonists. The marketing authorisation is based on a thorough analysis of the extensive safety and efficacy results and the assessment of the pivotal clinical trial program of the phase III. These results have shown that Acomplia at 20 mg per day (1 tablet) significantly reduces weight, waist circumference, HBA1c, triglycerides, at the same time improving significantly the patients’ HDL ("good cholesterol").

About sanofi-aventis

Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic
diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

 

 

 

 

Source: - http://www.medadnews.com